A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma

Despite emerging targeted and immunotherapy treatments, no monoclonal antibodies or antibody-drug conjugates (ADCs) directly targeting tumor cells are currently approved for melanoma therapy. The tumor-associated antigen chondroitin sulphate proteoglycan 4 (CSPG4), a neural crest glycoprotein over-e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Ricarda M., Crescioli, Silvia, Mele, Silvia, Sachouli, Eirini, Cheung, Anthony, Chui, Connie K., Andriollo, Paolo, Jackson, Paul J. M., Lacy, Katie E., Spicer, James F., Thurston, David E., Karagiannis, Sophia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226475/
https://www.ncbi.nlm.nih.gov/pubmed/32331483
http://dx.doi.org/10.3390/cancers12041029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226475/
https://www.ncbi.nlm.nih.gov/pubmed/32331483
http://dx.doi.org/10.3390/cancers12041029

Ejemplares similares